ArticleBMC cancer2025
Recognition of cancer chemotherapy adverse effect by patients: a cross-sectional study from Palestine.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coping styles mediate the association between sense of coherence and symptom distress in patients with colorectal cancer undergoing chemotherapy: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been suggested that patient awareness of chemotherapy-induced side effects is not uniform and may vary according to communication quality between healthcare providers and patients, educational initiatives, and the type of cancer and chemotherapy regimen. This study aimed to assess real-world chemotherapy-induced adverse effects as reported by cancer patients in the West Bank of Palestine and to identify key predictors of these side effects.
methodsThis cross-sectional study was conducted between January and December 2023 in various hospitals in the West Bank of Palestine. A validated questionnaire, previously developed and reviewed for face validity by a panel of experts, was administered to 266 consenting cancer patients receiving chemotherapy, and their electronic medical records were also reviewed. Descriptive statistics, chi-square/Fisher's exact tests, and multiple regression analyses were used to explore associations between sociodemographic/clinical variables and chemotherapy-induced adverse effects.
resultsThe median age of the 266 cancer patients was 48 [25-60] years. Overall, 91.7% of patients reported weakness, 88.0% reported hair loss, and 87.2% experienced vertigo, among other side effects. Multiple regression analyses revealed that a longer duration of chemotherapy sessions was a consistent predictor of increased adverse effects-specifically, it predicted higher frequencies of fever (Beta = 0.29, p < 0.001), vertigo (Beta = 0.29, p < 0.001), and weakness (Beta = 0.14, p = 0.031). Additionally, older age was associated with lower frequencies of fever (Beta = -0.28, p < 0.001) and skin toxicity (Beta = -0.30, p < 0.001), while female sex was linked to increased reports of weakness (Beta = 0.20, p = 0.003), hair loss (Beta = 0.25, p = 0.001), and edema (Beta = -0.22, p = 0.001).
conclusionThe findings underscore a substantial burden of chemotherapy-induced side effects among cancer patients treated in Palestinian hospitals, with treatment-related parameters-particularly the duration of chemotherapy sessions-significantly influencing the frequency of adverse effects. These results highlight the need for tailored counseling and personalized interventions that consider patient demographics and treatment characteristics to optimize care and improve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.